Esperion Therapeutics
ESPR
#6447
Rank
NZ$1.38 B
Marketcap
NZ$5.38
Share price
0.32%
Change (1 day)
271.15%
Change (1 year)

P/S ratio for Esperion Therapeutics (ESPR)

P/S ratio as of May 2026 (TTM): 2.65

According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.79. At the end of 2025 the company had a P/S ratio of 1.76.

P/S ratio history for Esperion Therapeutics from 2013 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20251.7630.1%
20241.35-53.75%
20232.92-51.95%
20226.0856.69%
20213.8831.08%
20202.96-73.21%
201911.1
2018N/A
2017N/A
2016N/A
2015N/A
2014N/A
2013N/A

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.28-14.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
4.42 66.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Ultragenyx Pharmaceutical
RARE
3.56 34.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
13.4 405.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
7.17 170.49%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
2.96 11.64%๐Ÿ‡บ๐Ÿ‡ธ USA